Behavioral variant frontotemporal dementia in patients with previous severe mental illness: a systematic and critical review

Demência frontotemporal variante comportamental em pacientes com transtorno mental grave prévio: revisão sistemática e crítica

Leandro Boson GAMBOGI1,2, Henrique Cerqueira GUIMARÃES1,2, Leonardo Cruz DE SOUZA1,2, Paulo CARAMELLI1,2

1Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Clínica Médica, Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento Belo Horizonte MG, Brasil; 2Universidade Federal de Minas Gerais, Programa de Pós-Graduação em Neurociências, Belo Horizonte MG, Brasil.

Leandro Boson Gambogi https://orcid.org/0000-0002-1268-8872; Henrique Cerqueira Guimarães https://orcid.org/0000-0002-6680-7099; Leonardo Cruz de Souza https://orcid.org/0000-0001-5027-9722; Paulo Caramelli https://orcid.org/0000-0002-4786-6990

Correspondence: Paulo Caramelli; Departamento de Clínica Médica - Faculdade de Medicina da UFMG; Avenida Alfredo Balena, 190 / Sala 246; 30130-100 Belo Horizonte MG, Brasil; E-mail: caramelli@ufmg.br

Conflict of interest: There is no conflict of interest to declare.

Received 26 November 2018; Received in final form 05 May 2019; Accepted 11 May 2019.

ABSTRACT

Objectives: To explore the relationship between severe/serious mental illness (SMI) and the behavioral variant of frontotemporal dementia (bvFTD), as the patterns of symptoms and cognitive performance that characterize both disorders share similarities. Methods: We performed a systematic review investigating what has already been published regarding the relationship between bvFTD and SMI. Studies were selected from PubMed and LILACS databases, including those published up to February 12, 2018. The search strategy included the following terms: “frontotemporal dementia” plus “bipolar”, OR “frontotemporal dementia” plus “schizophrenia”, OR “frontotemporal dementia” plus “schizoaffective”. Publications without abstracts, case reports with absent genetic or histopathological confirmation, reviews and non-English language papers were excluded across the search process. Results: The search on PubMed retrieved 186 articles, of which 42 met eligibility criteria. On the LILACS database, none met the requirements. Generally, three major research aims were identified: 1) to look for frontotemporal lobar degeneration-associated genetic abnormalities in patients with prior SMI; 2) to compare the cognitive profile between patients affected by neurodegenerative disorders and schizophrenic patients; 3) to highlight the association between bvFTD and preceding psychiatric conditions and/or distinguish them both. The investigated mutations were found infrequently in the studied SMI samples. Cross-sectional studies comparing cognitive performance between bvFTD and psychiatric disorders mostly found no remarkable differences. There were only a few case reports identifying definite frontotemporal lobar degeneration in patients with previous psychiatric diagnoses. Conclusions: The available evidence demonstrates how fragile the current understanding is regarding the association between bvFTD and prior SMI. Keywords: Bipolar disorder; frontotemporal dementia; psychotic disorders; schizophrenia.

RESUMO

Objetivos: Explorar a relação entre doença mental grave (DMG) e a variante comportamental da demência frontotemporal (DFTvc), uma vez que os padrões de sintomas e de desempenho cognitivo que caracterizam ambos os transtornos compõem semelhanças. Métodos: Revisão sistemática investigando estudos publicados sobre a relação entre DFTvc e DMG. Os estudos foram selecionados nas bases de dados PubMed e LILACS, incluindo aqueles publicados até 12 de fevereiro de 2018. A estratégia de busca incluiu os seguintes termos: “demência frontotemporal” e “bipolar”; “demência frontotemporal” e “esquizofrenia”; “demência frontotemporal” e “esquizoaffectiva”. Publicações sem resumos, relatos de casos sem confirmação genética ou histopatológica, revisões e artigos escritos em idiomas que não fossem o inglês não foram selecionados na busca sistemática. Resultados: A pesquisa no PubMed encontrou 186 artigos, dos quais 42 alcançaram critérios de elegibilidade. Na base de dados LILACS, nenhum dos nove artigos identificados atendeu aos requisitos. Foram identificados três objetivos de pesquisa principais: buscar anormalidades genéticas associadas à degeneração lobar frontotemporal (DLFT) em pacientes com SMI prévia; comparar o perfil cognitivo entre pacientes acometidos por doenças neurodegenerativas e esquizofrénicas; destacar a associação entre DFTvc e condições psiquiátricas precedentes e/ou distinguir ambos. As mutações investigadas foram encontradas infrequentemente nas amostras estudadas. Os estudos transversais comparando o desempenho cognitivo entre DFTvc e os transtornos psiquiátricos não encontraram diferença, e houve apenas relatos de casos confirmando de DLFT em pacientes com diagnósticos psiquiátricos prévios. Conclusões: A evidência disponível demonstra quão frágil é o entendimento atual sobre a associação entre DFTvc e DMG. Palavras-chave: Transtorno bipolar; demência frontotemporal; transtornos psicóticos; esquizofrenia.
Although mortality is higher and life expectancy is far shorter in people with severe/serious mental illness (SMI), recent epidemiological studies have suggested that this group of individuals is also affected, albeit to a minor extent, by the same demographic changes that have driven population aging worldwide. According to epidemiological research in other populations, it is reasonable to conceive that in these individuals with SMI, who are usually exposed to an unhealthy lifestyle, cognitive decline and overt dementia in the long run are probable outcomes if they reach old age. The relationship between severe psychiatric disorders and dementia has been recognized remotely, such as Kraepelin’s description of “dementia praecox”. Additionally, nowadays it is undisputed that psychiatric symptoms, such as mood changes, delusions, hallucinations, anxiety and others, constitute an essential hallmark of dementia.

The diagnosis of dementia in a person with a lifetime severe psychiatric disorder, such as severe relapsing unipolar depression, bipolar affective disorder (BD), and schizophrenia (SCZ) spectrum disorders is a challenging task. Most major neurocognitive disorders diagnostic proposals state that the patients’ deficits “should not be better explained” by a psychiatric condition. In fact, there is a general tendency to attribute to a basal disorder, either neurological or psychiatric, novel symptoms or signs allegedly arising from brain malfunction.

Unfortunately, however, there are few reports that have systematically evaluated the issue of dementia superimposing lifetime psychiatric disorders. It is unclear whether the dementia symptoms observed in these patients represent a new condition, such as Alzheimer’s disease (AD), but with phenotypic clinical features modified by the premorbid disorder; or whether in some individuals the observed cognitive decline should be regarded as a natural stage of the psychiatric disorder itself.

To accomplish this purpose, large cohorts of psychiatric patients should be followed for decades, with their cognitive and functional performance under objective evaluation, preferably with detailed longitudinal structural neuroimaging analyses and, critically, under a diagnostic framework that should recognize the presence of significant cognitive and functional decline as a dementia equivalent. To the best of our knowledge, a research project like this has not been conducted so far.

Meanwhile, the identification of genetic mutations—microtubule-associated protein tau gene (MAPT), progranulin gene (GRN), and chromosome 9 open reading frame 72 (C9orf72) gene, responsible for up to 15% of the frontotemporal lobar degeneration (FTLD) group of disorders—provide a framework to investigate cross-sectionally the prevalence of a neurodegenerative disease in this select group of patients. The advent of biomarkers related to AD in the cerebrospinal fluid (CSF) and positron emission tomography (PET) scans with beta-amyloid or tau tracers also allow a better investigation of neurodegenerative pathological substrates in this group of individuals with SMI.

Severe/serious mental illness is a clinical concept generally established by its duration and by the functional decline that it produces, encompassing disorders that cause psychotic symptoms, such as SCZ and schizoaffective disorder (SZA), and severe/psychotic presentations of affective disorders, such as severe major depression and BD. This concept is also replicated by the National Institute of Mental Health, which defines SMI as a mental, behavioral, or emotional disorder (excluding developmental and substance use disorders) of sufficient duration to meet diagnostic criteria specified within the Diagnostic and Statistical Manual of Mental Disorders (DSM), and resulting in serious functional impairment that substantially interferes with or limits one or more major life activities.

Bipolar affective disorder, SZA and SCZ, especially, may be grouped together as SMIs, not only by their severity, but also because they might be indistinguishable from a biological perspective. Clementz et al. based on multivariate analyses from cognitive, electroencephalographic, and oculomotor paradigms, identified three neurobiologically distinct psychosis biotypes previously classified within the psychosis dimension, and documented that each biotype included all DSM psychosis categories. The same three biotype constructs were later the objects of a study that examined whole brain gray matter density measures in probands, their relatives, and healthy individuals, organized by their biotype, and then by DSM diagnoses. The research pointed to brain anatomy characteristics, measured by reduced gray matter density, consistent with their cognitive and sensorimotor profile first described. The biotype 1 included individuals with a mean age of 35.3 years and mean age of illness onset of 20.5 years. The participants presented with severely impaired cognition and sensorimotor function, and had extensive and diffuse gray matter loss, more apparent in the frontal, anterior/middle cingulate cortex, and temporal regions. Poor-outcome individuals made up this group. The biotype 2 was typified by moderately impaired cognition and accentuated sensorimotor reactivity, with intermediate and more localized gray matter atrophy, more obvious in insula and frontotemporal regions. The mean age of the group was 35.4 years and mean age of onset of illness was 20.8 years; biotype 3, which had a mean age of 35.3 years and mean onset of illness at 20.3 years, presented with near-normal cognition and close to normal sensorimotor function, with small reductions in anterior limbic regions. Therefore, distinguishing an ongoing dementia process would be especially challenging for the most severely impaired groups, which already have brain anatomy abnormalities.

The diagnostic challenge of recognizing dementia in a patient with lifetime severe psychiatric disorder is far more puzzling when considering the possibility of behavioral variant frontotemporal dementia (bvFTD), in which many
patients do not routinely show gross cognitive deficits, particularly in their early stages. Several reports have documented that a large number of patients with bvFTD are, indeed, initially labeled with classical psychiatric conditions.9,10

To consider the relationship between SMI and bvFTD, we performed a systematic review investigating the available data regarding the interface between these conditions. First, we provide a very brief overview on the recent history of bvFTD and its neurobiological underpinnings, introducing the overlapping features between this type of dementia and primary psychiatric symptoms. Then we present the systematic review itself and discuss the available findings. Lastly, we present a critical analysis and propose a script to understand current evidence, which may be useful for future studies in the field.

FRONTOTEMPORAL DEMENTIA OVERVIEW

The predominant degeneration of the frontal and temporal cortex, first described in 1892 by Arnold Pick, usually induces a clinical presentation characterized by progressive behavioral and personality changes, and/or language impairment. Despite this long-standing description, formal diagnostic criteria and classification of clinical subtypes were first proposed only about 20 years ago and have been a subject of intense modification since then. Initially developed by a consensus of researchers in 1994, the criteria were subsequently refined by an international consensus in 1998 to include presentations with predominant language involvement. At that time, the term FTLD was proposed to define a group of a few pathological conditions associated with a broad spectrum of syndromes with overlapping clinical presentations, ranging from those with predominant behavioral changes to progressive language impairment. More recently, the clinical criteria for bvFTD diagnosis have been revised, substantially raising its sensitivity, albeit with a compromised specificity when used to tell it apart from FTLD and psychiatric disorders. Concurrently, the criteria for clinical characterization of primary progressive aphasia subtypes were detailed. This brief overview of the history of the frontotemporal dementia (FTD) description provides a sense of how recently clinical presentations of FTLD have been characterized, which in part accounts for the diagnostic difficulties encountered in clinical practice.

In parallel with advances in clinical characterization, mutations associated with FTLD have been identified since 1998, when mutations in the MAPT gene on chromosome 17 were first recognized in families with FTD and parkinsonism. Since the identification of MAPT mutations, over 10 other genes have been associated with FTLD spectrum disorders and, surprisingly, a single genetic mutation was found to account for completely different clinical pictures as well as for variable neuroimaging phenotypes. Despite this myriad of presentation possibilities, there is a clear tendency for a pattern of atrophy of the frontal and temporal brain regions. The main affected areas correspond to the medial frontal lobe and fronto-insular regions. Temporal lobes are also frequently affected and are even the most common site of atrophy in MAPT mutation individuals. Contemporary neuroscience is still dedicated to understanding the reasons for this convergent topographic involvement, despite a heterogeneous pathological background. Even more incipient is the understanding of the neurobiological role played by these brain regions, which are affected very early in the degenerative process that characterizes the FTLD spectrum, and can determine dramatically disturbing clinical presentations.

The frontal lobes and their multiple connections regulate essential aspects of human behavior, especially those resulting from the decision-making process. The frontal lobes also contribute to the processing of an additional repertoire of highly adaptive behaviors through afferents coming from the temporal lobes, especially from the polar region and the amygdala. The ability to regulate affective responses, adjusting them to the current social context and promoting adaptive prosocial attitudes, is also attributed to this interaction.

Such sophisticated behavioral adjustments are fundamental to a successful life, both from an individual and a societal point of view. This repertoire of behaviors is much vaster and ecologically far more relevant than the classical executive function performance, usually probed in artificially-set testing environments, through tasks relying on dorsolateral prefrontal cortex, which are heavily dependent on working memory and attentional control processes, and do not tap into the frontotemporal regions herein emphasized and critically important to FTD phenomenology. It is not surprising, therefore, that degenerative processes affecting these circuits, or psychiatric disorders that lead to their dysfunction, can be deeply disturbing to the patient’s daily functioning, despite mild-to-no impairment in classical neuropsychological tests. More recently, neuroimaging studies have demonstrated that there may be a common anatomo-functional underpinning between FTD and a few psychiatric conditions, at least in a small subset of patients.

SYSTEMATIC REVIEW

Methods

Studies were selected from PubMed and LILACS databases, including those published up to February 12, 2018. The search strategy included the following terms: “frontotemporal dementia” plus “bipolar”, OR “frontotemporal dementia” plus “schizophrenia”, OR “frontotemporal dementia” plus “schizoaffective”. Neither a publication date restriction nor a search field filter was used. This search strategy was...
augmented with manual searching through the reference lists from the included studies and was independently performed by two investigators (HCG and LBG).

Titles and abstracts of the papers - including publications ahead-of-print - retrieved in the initial search were screened and subsequently classified according to their own design characteristics: 1) case-control, 2) case reports, 3) cohort and 4) cross-sectional design studies. Publications without abstracts, case reports with absent genetic or histopathological confirmation, review articles, and papers written in non-English languages were not selected across the systematic search process.

**RESULTS**

The Figure shows the selected studies and the Table presents their findings.

The research on PubMed retrieved 186 articles, of which 42 matched eligibility criteria. On LILACS, none of the nine retrieved met the requirements. Therefore, 42 articles were selected, of which 10 were cohort studies, 12 were case-control studies, three were case-control studies, 12 were case reports, and 17 other studies were cross-sectional surveys. It was possible to identify three major research aims among the selected studies: 1) to look for FTLD-associated genetic abnormalities, mostly C9orf72 expansions, in psychotic, schizophrenic or bipolar patients; 2) to compare the cognitive profile between patients affected by neurodegenerative disorders and schizophrenic patients; 3) to highlight the association between bvFTD and preceding psychiatric conditions and/or distinguish them both.

The C9orf72 expansion was detected in 0.67% of a SCZ/SZA sample (n = 298) and in 0.57% of a sample of psychotic individuals (n = 697) (15, 20). However, this expansion was not found in four other cohorts of BD (n = 206), SCZ (n = 192, n = 466) and in treatment-resistant SCZ (n = 386) (16,18,19,22). Cross-sectional studies comparing the neurocognitive profile between bvFTD and psychiatric disorders mostly found no remarkable differences (44,45,47,51), or pointed to less severe deficits in bvFTD (48,55). Lastly, there were several case reports that established a definite FTLD diagnosis, through genetic or histopathological examination, in patients with previous diagnoses or clinical histories compatible with BD/SCZ/SZA or atypical psychiatric symptoms (28,29,30,31,32,33,34,35,36,37,38,39).

As shown in the Table, investigated mutations were found infrequently in the studied samples. Additionally, almost every large cohort studied did not look for mutations in a control group. The attempt to compare psychiatric disorders and neurodegenerative conditions clinically usually fails, considering that a few of these psychiatric patients might have already become demented by the time of the research evaluation, especially samples of severely affected individuals. Conversely, many case reports suggest a pathophysiological association between psychiatric disorders and FTLD, but more evidence is warranted to support this assumption.
Table. Synthesis of articles included in the present review.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Sample size</th>
<th>Participants</th>
<th>Type of study</th>
<th>Objectives</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Watson A et al.15, 2016</td>
<td>739</td>
<td>697 with psychosis; 42 base controls</td>
<td>Cohort</td>
<td>To identify C9orf72 expansion</td>
<td>Two pairs of related individuals had C9orf72 expansions.</td>
</tr>
<tr>
<td>Xu et al.16, 2015</td>
<td>386</td>
<td>Treatment-resistant schizophrenia</td>
<td>Cohort</td>
<td>To identify C9orf72 expansion</td>
<td>No abnormal hexanucleotide expansion was found.</td>
</tr>
<tr>
<td>Boutoleau-Bretonnière et al.17, 2015</td>
<td>89</td>
<td>36 bvFTD; 22 Alzheimer's disease; 15 progressive supranuclear palsy; 16 bipolar disorder</td>
<td>Cohort</td>
<td>To produce a behavioral inventory named DAPHNE. The aim was (1) to assess the validity and reliability of DAPHNE and (2) to evaluate its contribution to differentiating patients.</td>
<td>DAPHNE-6 allowed bvFTD diagnosis (score ≥ 4) with a sensitivity of 92%, while DAPHNE-40 (score ≥ 15) had a specificity of 92%.</td>
</tr>
<tr>
<td>Yoshino et al.18, 2015</td>
<td>466</td>
<td>Schizophrenia</td>
<td>Cohort</td>
<td>To identify C9orf72 expansion</td>
<td>No abnormal hexanucleotide expansion was found.</td>
</tr>
<tr>
<td>Floris et al.19, 2014</td>
<td>206</td>
<td>Bipolar disorder</td>
<td>Cohort</td>
<td>To identify C9orf72 expansion</td>
<td>No abnormal hexanucleotide repeat expansion was found.</td>
</tr>
<tr>
<td>Galimberti et al.20, 2014</td>
<td>298</td>
<td>Schizophrenia or schizoaffective disorder</td>
<td>Cohort</td>
<td>To identify C9orf72 expansion</td>
<td>The C9orf72 expansion was detected in 2 patients (0.67%).</td>
</tr>
<tr>
<td>Nicolas et al.21, 2014</td>
<td>96</td>
<td>Schizophrenia</td>
<td>Cohort</td>
<td>To accurately diagnose dementia and its type in a cohort of middle-aged patients with SCZ</td>
<td>Fourteen patients fulfilled diagnostic criteria for dementia. Four of them were diagnosed with possible or probable bvFTD.</td>
</tr>
<tr>
<td>Huey et al.22, 2013</td>
<td>192</td>
<td>Schizophrenia</td>
<td>Cohort</td>
<td>To identify C9orf72 expansion</td>
<td>No abnormal hexanucleotide repeat expansion was found.</td>
</tr>
<tr>
<td>Meisler et al.23, 2013</td>
<td>89</td>
<td>Bipolar disorder</td>
<td>Cohort</td>
<td>To identify C9orf72 expansion</td>
<td>The expansion frequency in this BD cohort was 1%.</td>
</tr>
<tr>
<td>de Vries et al.24, 2001</td>
<td>8</td>
<td>Schizophrenia patients with disorientation</td>
<td>Cohort</td>
<td>To describe the identification of dementia following SCZ, not better attributed to the psychiatric disorder itself.</td>
<td>Objective evidence of dementia was found in all patients, with a neuropsychological signature and SPECT findings similar to bvFTD.</td>
</tr>
<tr>
<td>Fahey et al.25, 2014</td>
<td>2477 controls: 1234; cases: 1243</td>
<td>Psychosis</td>
<td>Case-control</td>
<td>To compare the prevalence of C9orf72 expansion between psychosis patients and controls</td>
<td>No expansion &gt; 30 repeats was found. Expansions &gt; 22 repeats were similarly prevalent among patients and controls.</td>
</tr>
<tr>
<td>Bosia et al.26, 2012</td>
<td>315</td>
<td>220 schizophrenia; 48 bvFTD; 47 controls</td>
<td>Case-control</td>
<td>To evaluate the possible role of the Saitohin (Tau gene) polymorphism as a concurring factor of cognitive decline in SCZ</td>
<td>No significant difference in allelic distribution between the healthy controls and all other groups. Saitohin polymorphism predicted executive test performance in both patient groups.</td>
</tr>
<tr>
<td>Evin et al.27, 2002</td>
<td>46</td>
<td>Various neurodegenerative disorders</td>
<td>Case-control</td>
<td>To analyze the expression of AD-associated presenilin 1 (PS1) in various neurodegenerative disorders</td>
<td>Identified PS1 N- and C-terminal fragments similarly in the cortex of controls, Parkinson's, Huntington's, and SCZ individuals.</td>
</tr>
<tr>
<td>Rubino et al.28, 2017</td>
<td>1</td>
<td>An Italian male presenting with late-onset bipolar disorder</td>
<td>Case report</td>
<td>To report a case suggesting a possible link between BD, FTD and GRN mutations</td>
<td>In addition to FTD, progranulin may be involved in the neurobiology of BD type 1. Suggestion to screen patients with late-onset BD for GRN mutations.</td>
</tr>
<tr>
<td>Watanabe et al.29, 2017</td>
<td>1</td>
<td>A 58-year-old patient who had a sudden onset of disorganized behavior and meaningless speech. Psychotropic drugs were effective for catatonic symptoms</td>
<td>Case report</td>
<td>To report on a FTD patient who showed catatonia after the first episode of brief psychotic disorder</td>
<td>FTD with trans-activation response DNA-binding protein 43 presenting with a catatonic syndrome.</td>
</tr>
<tr>
<td>Authors</td>
<td>Sample size</td>
<td>Participants</td>
<td>Type of study</td>
<td>Objectives</td>
<td>Results</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Gramaglia et al.30, 2014</td>
<td>1</td>
<td>A 57-year-old Caucasian woman with a recent onset of bizarre behavior and mystic delusions</td>
<td>Case report</td>
<td>To describe a patient with bvFTD with a primary psychiatric presentation and a normal neurological examination</td>
<td>The C9orf72 expansion was detected.</td>
</tr>
<tr>
<td>Holm31, 2014</td>
<td>1</td>
<td>A patient with traumatic brain injury with subsequent depression and catatonia</td>
<td>Case report</td>
<td>To describe a patient with familial FTD with a primary psychiatric presentation, and typical response to standard treatment (lorazepam + electroconvulsive therapy) at the beginning</td>
<td>The C9orf72 expansion was detected.</td>
</tr>
<tr>
<td>Floris et al.32, 2013</td>
<td>1</td>
<td>A man who, from the age of 42 years, developed an affective disorder characterized by repeated manic and hypomanic episodes</td>
<td>Case report</td>
<td>To report on a patient suggesting a possible link between BD and FTLD</td>
<td>The C9orf72 expansion was detected.</td>
</tr>
<tr>
<td>Gourzis et al.33, 2012</td>
<td>1</td>
<td>A 29-year-old female patient previously diagnosed as having schizophrenia</td>
<td>Case report</td>
<td>To describe a young patient suffering from FTD, misdiagnosed as SCZ, suggesting the association between this clinical phenotype with a genetic defect on chromosome 1</td>
<td>The diagnosis of FTD was made clinically. Chromosomal analysis was conducted and revealed decrease in length of heterochromatin on the long arm of chromosome 1 (46, XX, 1qh−).</td>
</tr>
<tr>
<td>Khan et al.34, 2012</td>
<td>1</td>
<td>A 35-year-old woman who presented with new-onset of bizarre behavior and delusions</td>
<td>Case report</td>
<td>To make physicians aware of the potential overlapping symptoms and age at onset between some forms of bvFTD and SCZ</td>
<td>The patient was found to have a MAPT tau S356T mutation and a focal pattern of brain atrophy consistent with FTD.</td>
</tr>
<tr>
<td>Cerami et al.35, 2011</td>
<td>2</td>
<td>Two apparently-sporadic FTLD patients, with a premorbid bipolar disorder</td>
<td>Case report</td>
<td>To report two patients of definite FTLD with premorbid psychiatric symptoms</td>
<td>Medical history and genetic investigation revealed the presence of bipolar spectrum disorders and mutations in the GRN gene.</td>
</tr>
<tr>
<td>Momeni et al.36, 2010</td>
<td>2</td>
<td>A Latino family in which two siblings were diagnosed as having either schizophrenia or frontotemporal dementia</td>
<td>Case report</td>
<td>To characterize GRN mutations in the affected individuals</td>
<td>The siblings both have loss-of-function GRN mutations.</td>
</tr>
<tr>
<td>Momeni et al.37, 2010</td>
<td>2</td>
<td>Familial FTD with an exceptionally early age at onset. Both the proband and the proband’s father were initially diagnosed as having schizophrenia</td>
<td>Case report</td>
<td>To report a novel exon 12 mutation in MAPT (S356T) causing familial bvFTD</td>
<td>Pathological examination showed FTLD with extensive neuronal and glial tau deposition.</td>
</tr>
<tr>
<td>Stone et al.38, 2003</td>
<td>1</td>
<td>A 22-year-old man who had presented six years previously with symptoms that were initially attributed to schizophrenia</td>
<td>Case report</td>
<td>To report on a patient and to raise awareness that FTD should be considered in patients in their early 20s with SCZ and negative symptoms, who display frontotemporal dysfunction and have a relentlessly progressive course</td>
<td>Magnetic resonance imaging and neuropathology obtained at brain biopsy suggest a diagnosis of non-Pick’s FTD.</td>
</tr>
<tr>
<td>Waddington et al.39, 1995</td>
<td>1</td>
<td>A woman with a consistent clinical diagnosis of typical schizophrenia</td>
<td>Case report</td>
<td>To report on a patient and to report ‘schizophrenia-like’ psychosis as a prodrome of Pick’s disease</td>
<td>The neuropathological hallmarks of Pick’s disease were present.</td>
</tr>
</tbody>
</table>

Continue
<table>
<thead>
<tr>
<th>Authors</th>
<th>Sample size</th>
<th>Participants</th>
<th>Type of study</th>
<th>Objectives</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baez et al. 40, 2019</td>
<td>51</td>
<td>16 bvFTD/ 13 Bipolar disorder/ 22 controls</td>
<td>Cross sectional</td>
<td>The compare the executive functions (EF) and social cognition profiles as well as the structural neuroimaging of bvFTD and elderly patients with BD.</td>
<td>bvFTD patients showed deficits in working memory, abstraction capacity, inhibitory control, cognitive flexibility, verbal fluency and theory of mind (ToM). Patients with BD showed lower performance than controls in terms of abstraction capacity and verbal inhibitory control. In bvFTD patients, atrophy of frontal, temporal and insular cortices was related to EF deficits. Atrophy of the amygdala, the hippocampus, the parahippocampal gyrus, the putamen, the insula, the precuneus, the right temporoparietal junction and superior temporal pole was associated to ToM impairments. No significant associations between atrophy and EF performance were observed in BD patients. BvFTD patients showed greater EF and ToM deficits than BD patients. Moreover, compared to BD, bvFTD patients exhibited a significant decrease in GM volume in frontal, temporal and parietal regions.</td>
</tr>
<tr>
<td>Metin et al. 41, 2018</td>
<td>38</td>
<td>18 bvFTD/ 20 late-life Bipolar disorder</td>
<td>Cross sectional</td>
<td>To compare differential diagnosis ability of electrophysiological and neuroimaging findings in BD and bvFTD, aimed to show their classification power using an artificial neural network and genetic algorithm based approach</td>
<td>The artificial neural network method classified BD from bvFTD with 76% overall accuracy only by using on EEG power values. The radiological diagnosis classified BD from bvFTD with 79% overall accuracy. The radiological diagnosis added to the EEG analysis, classified with 87% overall accuracy.</td>
</tr>
<tr>
<td>Vijverberg et al. 42, 2017</td>
<td>381</td>
<td>42 major depression/ 41 Bipolar disorder/ 47 schizophrenia/ 173 bvFTD/ 78 controls</td>
<td>Cross sectional</td>
<td>To compare neuropsychological profiles in bvFTD with its most common primary psychiatric differential diagnoses.</td>
<td>Cognitive deficits in bvFTD are less severe than in primary psychiatric disorders with active symptoms. 34% of bvFTD showed psychotic features. C9orf72 expansion cases were more likely to exhibit psychotic symptoms than non-carriers (64% vs. 26%; p = 0.006). Increased psychotic symptoms in C9orf72 expansion carriers correlated with atrophy in a distributed cortical and subcortical network that included discrete regions of the frontal, temporal and occipital cortices, as well as the thalamus, striatum and cerebellum.</td>
</tr>
<tr>
<td>Devenney et al. 43, 2016</td>
<td>79</td>
<td>56 bvFTD/ 23 healthy controls</td>
<td>Cross sectional</td>
<td>To address the gap in the literature regarding the severity and underlying neural correlates of psychotic symptoms in frontotemporal dementia with and without the C9orf72 gene expansion.</td>
<td></td>
</tr>
<tr>
<td>Authors</td>
<td>Sample size</td>
<td>Participants</td>
<td>Type of study</td>
<td>Objectives</td>
<td>Results</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>--------------</td>
<td>--------------</td>
<td>------------</td>
<td>---------</td>
</tr>
<tr>
<td>Chan et al.44, 2015</td>
<td>50</td>
<td>7 inpatients with schizophrenia/ 13 community-dwelling outpatients with /12 bvFTD/ 18 healthy controls</td>
<td>Cross sectional</td>
<td>To compare neurocognitive performance across groups in 16 cognitive domains</td>
<td>Their findings revealed a similar cognitive profile among schizophrenia inpatients and bvFTD groups, compared with schizophrenia outpatients’ group, which outperformed the former two groups.</td>
</tr>
<tr>
<td>Chan et al.45, 2014</td>
<td>60</td>
<td>26 schizophrenia/ 34 bvFTD</td>
<td>Cross sectional</td>
<td>To compare retrospectively the neuropsychological performance of schizophrenia and frontotemporal dementia patients.</td>
<td>Cognitive impairment was similar in degree and pattern between groups.</td>
</tr>
<tr>
<td>Nishida et al.46, 2013</td>
<td>93</td>
<td>18 mild FTD/ 20 schizophrenia/ 18 mild Alzheimer’s disease/ 37 age matched controls</td>
<td>Cross sectional</td>
<td>To compare resting EEG patterns, related to resting-state fMRI networks, among groups.</td>
<td>The duration of class C was significantly shorter in FTD than in controls and AD, and the duration of class D was significantly shorter in schizophrenia than in controls, FTD and AD.</td>
</tr>
<tr>
<td>Weickert et al.47, 2013</td>
<td>70</td>
<td>20 FTLD/24 schizophrenia/ 26 controls</td>
<td>Cross sectional</td>
<td>To investigate and compare probabilistic association learning between schizophrenia and FTLD patients.</td>
<td>There was no difference in performance between FTLD and schizophrenia groups.</td>
</tr>
<tr>
<td>Bediou et al.48, 2012</td>
<td>214</td>
<td>Several neurodegenerative disorders and schizophrenia patients</td>
<td>Cross sectional</td>
<td>To compare Facial Emotion Recognition test performance across several groups, and investigate the influence of dopaminergic drugs on these findings.</td>
<td>FTD patients presented the worst performance across all groups. Symptomatic schizophrenia patients stood between FTD and AD groups, and as similar as Parkinson’s disease patients.</td>
</tr>
<tr>
<td>Woolley et al.49, 2011</td>
<td>252</td>
<td>Several neurodegenerative disorders</td>
<td>Cross sectional</td>
<td>To identify rates of and risk factors for psychiatric diagnosis preceding the diagnosis of neurodegenerative disease, retrospectively by chart review.</td>
<td>bvFTD patients received a prior psychiatric diagnosis significantly more often than other dementia types and were also more likely to receive a diagnosis of bipolar disorder or schizophrenia. Negative and frontal lobe symptoms were similarly present in both groups. Negative scores were higher in schizophrenia and frontal lobe behaviors were more pronounced in bvFTD.</td>
</tr>
<tr>
<td>Ziauddeen et al.50, 2011</td>
<td>23</td>
<td>12 schizophrenia/ 11 bvFTD</td>
<td>Cross sectional</td>
<td>To compare clinical and neuropsychological features between schizophrenia patients with predominant negative symptoms and bvFTD.</td>
<td>The morbid risk for schizophrenia was significantly higher in relatives of frontotemporal dementia probands.</td>
</tr>
<tr>
<td>Schoder et al.51, 2010</td>
<td>200</td>
<td>100 first-degree relatives of bvFTD patients/ 100 first-degree relatives of AD patients</td>
<td>Cross sectional</td>
<td>To calculate de morbid risk of schizophrenia in first-degree relatives</td>
<td>The morbid risk for schizophrenia was significantly higher in relatives of frontotemporal dementia probands.</td>
</tr>
<tr>
<td>Foley et al.52, 2009</td>
<td>185</td>
<td>37 geriatric schizophrenia-spectrum disorders (SSD) / 41 bvFTD / 107 controls</td>
<td>Cross sectional</td>
<td>To address whether measures for assessing premorbid intellectual functioning are adequate for geriatric schizophrenia</td>
<td>Analysis showed unique patterns of spared function in when compared to FTD and controls.</td>
</tr>
<tr>
<td>Velakoulis et al.53, 2009</td>
<td>17</td>
<td>Patients with bvFTD who had symptoms onset before 60 years.</td>
<td>Cross sectional</td>
<td>To investigate the relationship between early age at onset and psychotic presentations in pathologically verified definite bvFTD patients.</td>
<td>Five out of 17 patients had presented psychotic symptoms.</td>
</tr>
</tbody>
</table>
DISCUSSION

Most of the evidence gathered from the systematic review process does not clarify the link between lifelong SMI and dementia, precluding reliable assumptions regarding this disputed issue. Nevertheless, a few studies suggested the possibility, under a structured diagnostic proposal, of formally recognizing an equivalent to dementia syndrome in selected psychiatric patients.

Here we present a critical analysis, combining the main findings of this review and other related publications in the field suggesting directions for future research.

Severe mental illness natural outcomes

Making a diagnosis of dementia in a patient with lifelong SMI is challenging. Cognitive and functional impairment constitute plausible outcomes from the premorbid mental illness itself and impairment in cognitive performance does not exclude primary psychiatric diagnoses in a dementia workup52. Indeed, long-term cognitive and functional outcomes from severe psychiatric illness—BD, SZA or SCZ—are still a source of an intense debate. Accordingly, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), in its “Functional Consequences of Bipolar I and II Disorders” topics, recognizes functional impairment in approximately 30% of patients with BD type I and in at least 15-20% of those with BD type II. The DSM-5 also reserves a topic to discuss the “Functional Consequences of Schizophrenia” and states that significant social and functional impairment are associated with SCZ55.

The very concept of SCZ emerged in 1896, with Kraepelin’s description of dementia praecox. He emphasized the progressive nature of the disease, which almost invariably proceeded to cognitive and behavioral deterioration. At that time, the unfortunate prognosis associated with this disorder seemed to suggest to him the idea of a possible neurodegenerative condition. Additionally, in the so-called manic-depressive insanity, Kraepelin noticed the relapsing nature of mood disorders; however, recognizing the ordinary possibility of full recovery between depressive or manic episodes. Nevertheless, within a scenario of decreasing intercrisis intervals and increasing duration of episodes along the disease course, Kraepelin considered a worse prognosis, admitting the possibility of a “psychic decline” in these patients. It is interesting to point out that Kraepelin’s description of patients with chronic mania share many behavioral features that constitute core diagnostic symptoms of bvFTD56.

In SCZ, the remission rate from a first psychotic episode is estimated to be around 70% in the first year but remains almost unchanged over the course of the disease. Functional recovery is less frequently achieved (18–40%), namely living independently without psychotic or negative symptoms while working or studying, but this rate does not change over time, contradicting the idea of a progressive condition. Patients with psychotic disorders showed IQ deficits and developmental delays in specific cognitive domains during the first two decades of life, in a cohort study57. Hence, the cognitive impairment of these patients is suggested to be linked to a neurodevelopmental cause.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Sample size</th>
<th>Participants</th>
<th>Type of study</th>
<th>Objectives</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Velakoulis et al.52, 2009</td>
<td>23</td>
<td>12 Schizophrenia/3 Bipolar disorder/11 controls</td>
<td>Cross sectional</td>
<td>To determine whether FTD-like abnormalities in TARDNA binding protein (TDP-43) and ubiquitin are detectable in hippocampal dentate gyrus of patients with schizophrenia and bipolar disorder</td>
<td>The regular nuclear expression of TDP-43 was not detected in 3 patients.</td>
</tr>
<tr>
<td>Foley et al.53, 2008</td>
<td>185</td>
<td>37 geriatric schizophrenia-spectrum disorders / 41 bvFTD / 107 controls</td>
<td>Cross sectional</td>
<td>To investigate pattern of memory deficits across groups.</td>
<td>Failed to find differences between groups on pattern of memory impairment.</td>
</tr>
<tr>
<td>Kosmidis et al.54, 2008</td>
<td>63</td>
<td>28 schizophrenia plus 26 age-matched controls / 9 bvFTD plus 10 age-matched controls</td>
<td>Cross sectional</td>
<td>To investigate social cognition and theory of mind across groups using videotaped scenarios of social interactions.</td>
<td>Both groups displayed generalized impairments in comprehension of social interactions. Schizophrenia patients were not impaired in evaluating sincere remarks. bvFTD patients were markedly impaired in recognizing sarcasm, specially when non-verbal cues were minimal.</td>
</tr>
</tbody>
</table>

bvFTD: behavioral variant frontotemporal dementia; FTLD: frontotemporal lobe dementia; FTD: frontotemporal dementia; SCZ: schizophrenia; BD: bipolar disorder; AD: Alzheimer’s disease.
In cognitive testing, patients with well-controlled SCZ usually display performances between 1.0 and 1.5 standard deviations below a reference control group. This deficit corresponds to a mild neurocognitive disorder and is generally incompatible with dementia, where performance is typically 2.0 standard deviations or more below the mean, according to the DSM-5. Conversely, approximately 25% of SCZ patients can be categorized as having a poor cognitive and functional prognosis. Nonetheless, studies that have addressed this issue have not ventured into characterizing a formal diagnosis of dementia in these individuals. The group with a poor outcome would encompass "Kraepelinian" SCZ, with permanent cognitive impairment and performance similar to bvFTD patients. In searching for the overlapping diagnosis of dementia and SCZ, Nicolas et al. found 14 individuals who fulfilled the criteria for dementia in a cohort of 96 SCZ patients followed for 20 months. Interestingly, four of them met criteria for bvFTD.

Schizophrenic patients usually have social cognition disturbances as a manifestation of the illness. Therefore, Kosmidis and colleagues compared bvFTD and SCZ individuals using videotaped scenarios of social interactions illustrating sincere, sarcastic and paradoxical statements. The results indicated that the SCZ group had impaired performances on all theory of mind conditions, despite understanding sincere statements. Nonetheless, bvFTD patients had remarkable impairment in identifying sarcasm, and seemed to benefit from verbal tips that indicated the appropriate social context, suggesting that these patients were particularly impaired in detecting discrete nonverbal signs from the scene. In another study, Bediou et al. explored facial emotional recognition performance in different clinical conditions, including SCZ and bvFTD. Their results showed impaired efficiency in both groups of patients when compared with their respective controls. The bvFTD group displayed poorer performance in comparison with the SCZ group.

Patients with BD seem to present with cognitive impairment in all phases of the disease, including periods of remission, and it has been suggested that cognitive performance declines according to the number of accumulated mood disorder episodes. Patients with BD share a similar cognitive profile with those with SCZ, including impairment in verbal memory, as well as in executive function and verbal fluency tests. Despite this similarity, there seems to be a severity spectrum across these disorders, in which BD patients display a better performance than those with SCZ, and SZA patients stand in between them.

Overlapping disorders

**Psychiatric presentations in bvFTD**

Personality changes and inappropriate social behaviors are core features of bvFTD, including decline in interpersonal and social conduct, emotional blunting and loss of insight. Almost routinely, the behavioral symptoms precede marked cognitive decline. As a result, patients with early behavioral changes of bvFTD are more likely to seek specialized psychiatric help and usually receive a cardinal psychiatric disorder diagnosis. In this sense, the use of a behavioral inventory appears to be the best assessment method to diagnose bvFTD.

Some of the initial symptoms of bvFTD, such as apathy, disininterest and lack of initiative, are often mistakenly diagnosed as major depression. On the other hand, disinhibition, hypersclexia, compulsive behaviors and decreased need for sleep may be confused with the mania/hypomania symptoms of BD. Indeed, after major depressive disorder, BD was the most frequently given diagnosis in a cohort of bvFTD patients, of whom almost 50% were diagnosed with a primary psychiatric disorder before bvFTD was finally recognized. It is worth noting that Gossink and colleagues found different results (past psychiatric disorder in only 8.7% of individuals), albeit using a different set of inclusion criteria. They prospectively evaluated the prevalence of a past psychiatric disorder in a large cohort of bvFTD in a structured interview. Nonetheless, this study did not consider the severe lack of insight in patients with bvFTD, and investigated the past psychiatric history of the patients by interviewing them directly, without the contribution of a trustworthy proxy.

Psychotic symptoms have been reported in about 10-20% of bvFTD patients, in spite of this not being considered a core symptom in diagnostic criteria. Therefore, this presentation may easily be mistaken for schizophrenic symptoms, particularly in those with C9orf72 gene expansions. The emotional blunting displayed by bvFTD patients is akin to the one classically described by Bleuler in the "Group of Schizophrenias", a cluster of symptoms later categorized as part of the negative presentation of the disease in 1974. In 1988, Weinberger noted that these symptoms were "phenomenologically similar to many of the characteristics of patients with disease of the frontal lobe", later confirmed by Ziauddeen and colleagues.

In fact, primary psychiatric disorders and bvFTD may be almost indistinguishable under the concept of late-onset frontal lobe syndrome. Vijverberg and colleagues have investigated which demographic, clinical, neuropsychological, neuroimaging, and CSF biomarkers are important in distinguishing primary psychiatric disorders presenting as late-onset frontal lobe syndrome, from bvFTD. These authors suggested that late-onset primary psychiatric disorders may show neuroimaging abnormalities, especially metabolic deficits akin to FTD, in FDG-PET, which poses further difficulty in obtaining a correct differential diagnosis on a cross-sectional basis. Nevertheless, they found that specific CSF biomarkers—total tau, phosphorylated tau, amyloid-β 1-42 peptide and neurofilament light chain concentrations—may aid clinicians in the diagnostic workup. Also, in an attempt to contribute to the distinction between primary psychiatric
disorders and bvFTD, Metin and colleagues used quantitative electroencephalography for differentiating bvFTD from late-life BD with 76% overall accuracy41.

**Definite FTLD disguised as primary psychiatric disorders**

Velakoulis et al.6 hypothesized that very young-onset bvFTD could masquerade as a SCZ or BD presentation. In a clinicopathological study, they found that five out of 17 FTLD patients had received a previous diagnosis of psychotic illness. Genetic analysis in one of these patients showed a mutation in the GRN gene. Additionally, in their literature review, the authors also found that a third of FTD patients aged 30 years or less, and a quarter of those aged 40 years or less, had received a primary diagnosis of psychosis. Indeed, early-onset bvFTD patients, whose presentation included psychotic symptoms, social withdrawal, emotional blunting, functional decline and mild executive dysfunction, were likely to have received a diagnosis of SCZ.

Velakoulis et al.42 also investigated the presence of TDP-43 neuropathology, related to FTLD, in brain sections of 12 deceased SCZ and BD patients. They identified three individuals with TDP-43 neuropathological changes. Interestingly, all three individuals had late-onset psychotic features, notable impairment in decision-making and a positive family history for SMI52, similar to bvFTD. Following the same reasoning, Meisler and colleagues demonstrated that the C9orf72 repeat expansion may be associated with a classic clinical presentation of BD and a later progression to neurodegenerative disease. The same mutation was considered a possible, albeit rare, cause of SCZ in European and North American cohorts12,20. Conversely, this mutation was not found in three other studies, two of them in Asian cohorts16,18,22.

There are frequent reports of lifelong psychiatric disorders, especially BD, describing patients in whom a definite bvFTD diagnosis was made through the identification of fully penetrant genetic abnormalities (C9orf72 and GRN), suggesting the possibility of a diagnostic superimposition of these two conditions, and the need for a debate on the relationship between them28,32,35. In the pursuit of the association between FTLD and primary psychiatric disorders, Schoder and colleagues investigated the risk of SCZ and SZA in first-degree relatives of patients with FTLD, and found a higher risk in this group of individuals in comparison with relatives of AD patients40.

**Neuroprogression models in severe mental illness and the neuroinflammatory pathway**

Increased blood levels of a wide range of cytokines in patients with primary psychiatric disorders, such as depression, BD and SCZ, have been documented, indicating a possible role of pro-inflammatory pathway neurotoxicity65.

In SCZ, neurotoxicity associated with a psychotic crisis was suggested by Wyatt66. Moreover, the duration of untreated symptoms has been correlated to a reduction of gray matter volumes in several reports67. Although neuroimaging studies showed structural developmental changes in the first psychotic episode, with subsequent reduction in brain tissue volume over the years, secondary causes, such as use of antipsychotics and other drugs, could alternatively explain the observed atrophy68.

In BD, there have been increasing suggestions that chronic inflammatory processes, both from periphery and within the brain, are involved in its pathophysiology. Post proposed the foundations of our current knowledge regarding neuroprogression69. This phenomenon was further elaborated on by Kapczinski et al. to explain long-term outcomes of BD in brain structure, patient cognition, functionality and response to treatments70. It is noteworthy that the neuroprogression and staging models of severe psychiatric disorders accepted stages compatible with a diagnosis of dementia late in the course of these diseases70. These are theoretical models that do not clarify the mechanism that underpins this impressive change in the disease course. They also fail to contemplate the possibility that another superimposed disease might be in progress. Additionally, these models do not elucidate why many individuals do not progress to dementia as an end-stage BD.

Dols and colleagues described four patients with lifetime BD71 who evolved to a bvFTD phenotype, showing a behavioral profile very different from these individuals’ previous levels of functioning. The authors admitted that the clinical picture could not be better explained by the patients’ primary psychiatric disease course nor could it be explained by BD staging models, as the patients had few prior severe mood disorder episodes. The authors did not propose a neurodegenerative condition as a reliable explanation for their findings. After all, their patients had cognitive performances that were regarded as only mildly impaired, had no neuroimaging abnormalities, and did not show cognitive decline during follow-up. It is noteworthy that our group retrospectively studied patients with a similar clinical history to Dols71, but in the findings by Gambogi et al.72, including neuroimaging and cognitive testing, there were only subtle differences in a typical bvFTD patient. Gambogi et al. found that the frequency of antipsychotic drug use, primitive reflexes, apathy, stereotypic/compulsive/ritualistic behaviors, and family history of psychosis were statistically higher in bvFTD patients with a prior history of SMI than in patients with typical bvFTD. The former group of patients also showed a higher severity of neuropsychiatric symptoms and worse performance in the Frontal Assessment Battery72.

Unfortunately, studies of progressive neuroimaging changes in BD patients showed unreplicated and contradictory findings, such as increased gray matter volume in the prefrontal cortex, limbic and subcortical structures73. On the other hand, some reports pointed to a decrease in gray matter volume in orbital and medial prefrontal cortex, in addition to
smaller volumes in medial temporal cortex and ventral striatum. Moreover, some patients may have greater volumes in the third and fourth ventricles, and these structural changes tend to be worse in patients with recurrent episodes.

Although the effective interplay between peripheral mediators and the inflammatory phenomena of brain tissue is not precisely known, the intense communication between circulating cytokines and leukocytes and the central nervous system is undisputed nowadays. This phenomenon is processed across the blood-brain barrier through intense communication among neurons, glial cells and endothelial cells, whose luminal surface is in permanent contact with the vascular content. In fact, the role of inflammatory tissue activation in the vicinity of neuropathological markers of classic neurodegenerative diseases has been recognized for some time. Furthermore, animal models of some of these diseases have shown that the peripheral inflammatory stimulus may aggravate previous cognitive deficits, and even accelerate the neuropathological process per se. In prospective studies with elderly human cohorts, documentation of episodic systemic infection, such as pneumonia, increased the subsequent incidence of dementia. Furthermore, in observational studies the use of nonsteroidal anti-inflammatory drugs was found to be associated with lower risk for dementia in exposed individuals.

These combined data suggest that systemic inflammatory factors, with SCZ or BD hypothetically included, may contribute to the phenomenon of progressive cognitive decline.

Atypical presentations of FTLD

Recently, it has become possible to identify individuals carrying genetic mutations or expansions. Hence, a range of possibilities for research in FTLD has been opened, allowing in vivo investigation of endophenotypes in carrier individuals who do not yet present with the clinical disease itself. Studies comparing supposed asymptomatic MAPT mutation carriers with controls have highlighted brain connectivity changes years before the expected disease onset, according to their affected relatives’ average clinical course. Interestingly, connectivity changes share a similar topography with brain regions classically targeted by atrophy in symptomatic individuals. Indeed, the idea of SCZ as a prodrome of a neurodegenerative disease had already been proposed by Waddington et al. and by Khan et al. The former study established all the neuropathological hallmarks of Pick’s disease in a biopsy from a woman with a typical schizophrenic picture. The latter study confirmed MAPT mutation in a 35-year-old patient with an initial schizophreniform presentation and typical pattern of brain atrophy.

Symptomatic patients carrying GRN mutations show reduced plasma progranulin levels and this same finding was evident in asymptomatic carriers in their second or third decades of life. In addition, mutations in the GRN gene had already been linked to SCZ and BD, with equal reduction of plasma protein levels in carriers. Moreover, both MAPT and GRN genes mutation carriers may exhibit structural and functional connectivity changes that precede the first symptoms of bvFTD. These changes are characterized by progressive reduction of fractional anisotropy through diffusion tensor imaging, and resemble abnormalities found in patients with BD, especially in the uncinate fasciculus. These findings support the idea that psychiatric manifestations could be the prodromal phase of neurodegenerative diseases.

The definite confirmation of a pathological substrate associated with FTLD in patients with a psychiatric history, and the inversely proportional relationship between age at onset and the schizophreniform presentation (the younger, the more prevalent the presentations), suggest the possibility of a phenomenon already observed in other neurodegenerative diseases such as leukodystrophy and Niemann-Pick Type C disease. For reasons still not understood, these diseases sometimes manifest in adults or in the elderly, indicating a slow progression. It is reasonable to consider that psychosis might be a nonspecific psychiatric symptom, resulting from the reaction of the still-resilient young brain to the underlying neurodegenerative process.

Finally, the slowly-progressive degenerative phenomenon has been repeatedly reported in the literature, especially in individuals with bvFTD carrying the C9orf72 expansion. The relevance of this finding for the scope of the discussion presented here is particularly important, given that this etiologic subtype of FTD has consistently been associated with psychotic presentations.

CONCLUSIONS

The available evidence discussed herein demonstrates how fragile the current understanding is regarding the association between FTD and prior SMI. The issue of misdiagnosis between these conditions is strongly emphasized in many reports.

Dementia superimposed on a severe psychiatric clinical picture, where cognitive impairment and cerebral atrophy arise early from neurodevelopment issues, is a plausible outcome, particularly when considering cognitive and brain reserve contemporary concepts. The underlying neuropathology remains unknown though. However, cases like those described by Dols et al. and by Gambogi et al. could not be explained from this perspective. This group of patients deserves a different evaluation workup. If dementia ensues, prognostic predictions and therapeutic choices might be revised. Special attention should be paid to late onset, atypical phenotypes, and to those patients with an unfavorable evolution. In these patients, we suggest the development of investigative algorithms comprising neuropsychological assessment, multimodal neuroimaging, genetic tests, and other biomarkers, including CSF analysis and, perhaps, peripheral inflammatory biomarkers. There is an urgent need...
to reframe the clinical point of view that seems permissive toward progressive or severe cognitive and functional decline in supposed primary psychiatric conditions.

Acknowledgments

Leonardo Cruz de Souza and Paulo Caramelli are funded by CNPq, Brazil (bolsa de produtividade em pesquisa).

References

24. de Vries PJ, Honer WG, Kemp PM, McKenna PJ. Dementia as a complication of schizophrenia. J Neurol Neurosurg Psychiatry. 2001 May;70(5):588-96. https://doi.org/10.1136/jnnp.70.5.588


Foley, J; Golden, C; Simco, E; Schneider B; McCue R; Shaw L. Corollary- and discrepancy-based approaches for examining the appropriateness of premorbid cognitive estimation in frontotemporal (FTD) and Alzheimer's disease. Int J Neuropsychol. 2009;119(10):1810-39. https://doi.org/10.1002/jp.20019


Gambozi LB et al. Frontotemporal dementia and severe mental illness 667


